153381-59-0

Basic information

• Product Name: 3-<1-(phenylhydrazono)-D-erythro-2,3,4-trihydroxybutyl>quinoxalin-2-one
• Synonyms: 3-<1-(phenylhydrazono)-D-erythro-2,3,4-trihydroxybutyl>quinoxalin-2-one
• CAS NO: 153381-59-0
• Molecular Weight: 354.365
• Mol File: 153381-59-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3-<1-(phenylhydrazono)-D-erythro-2,3,4-trihydroxybutyl>quinoxalin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-<1-(phenylhydrazono)-D-erythro-2,3,4-trihydroxybutyl>quinoxalin-2-one(153381-59-0)
• EPA Substance Registry System: 3-<1-(phenylhydrazono)-D-erythro-2,3,4-trihydroxybutyl>quinoxalin-2-one(153381-59-0)

Safety Data

• Hazardous Substances Data: 153381-59-0(Hazardous Substances Data)

Upstream product

• 95-54-5 1,2-diamino-benzene 
• 100-63-0 phenylhydrazine 
• 89-65-6 isoascorbic acid 

Downstream Products

• 67912-27-0 1-Methyl-3-(D-erythro-2,3,4-trihydroxy-1-phenylhydrazonobutyl)-2(1H)-quinoxalinone 
• 142940-62-3 3-(2-acetamido-3,4-dihydroxy-1-phenylhydrazonobutyl)-2(1H)-quinoxalinon 
• 142940-66-7 3-(1-Acetamido-1-deoxy-D-glycerol-1-yl)-1-phenyl-1H-pyrazolo<3,4-b>quinoxaline 
• 142940-63-4 N-{(S)-2,3-Dihydroxy-1-[(4-methyl-3-oxo-3,4-dihydro-quinoxalin-2-yl)-(phenyl-hydrazono)-methyl]-propyl}-acetamide 
• 142940-67-8 Acetic acid (S)-1-acetoxymethyl-2-acetylamino-2-(1-phenyl-1H-pyrazolo[3,4-b]quinoxalin-3-yl)-ethyl ester 
• 142940-64-5 3-(D-2-Acetamido-3,4-diacetoxy-1-phenylhydrazonobutyl)-2(1H)-quinoxalinone 
• 142940-65-6 3-(D-2-Acetamido-3,4-diacetoxy-1-phenylhydrazonobutyl)-1-methyl-2(1H)-quinoxalinone 
• 142940-60-1 1-Methyl-3-(D-erythro-2,3,4-triacetoxy-1-phenylhydrazonobutyl)-2(1H)-quinoxalinone 

Relevant articles and documents

Addition and cyclisation reactions of sugar phenylhydrazone derivatives via a 1,4-elimination process: preparation of 3-(2-acetamido-1-phenylhydrazonobutyl)-2(1H)-quinoxalinone and 3-(1-acetamidopropyl)-pyrazolquinoxaline (flavazole) derivatives

Acetylation of 3-(L-threo-2,3,4-trihydroxy-1-phenylhydrazonobutyl)-2(1H)-quinoxalinone derivatives (1a and 1c) and of the D-erythro diastereomers (1b and 1d), prepared from L-ascorbic acid and D-isoascorbic acid, respectively, and then treatment of the pr